Start here if you're new
what it is
Galectin Therapeutics develops a drug candidate for fibrosis, cancer, and other diseases.
how it gets paid
Last year Galectin Therapeutic made n/a in revenue.
what just happened
The last quarter showed a -$0.40 EPS, while revenue stayed undisclosed.
At a glance
C+ balance sheet — struggling to keep the lights on
75/100 earnings predictability — reasonably predictable
-$0.76 fy2024 eps est
1.1 beta
~$199M market cap
xvary composite: 26/100 — weak
What they do
Galectin Therapeutics develops a drug candidate for fibrosis, cancer, and other diseases.
Belapectin, the lead candidate → the main drug being tested → if it works, the whole company gets a reason to exist. You are not buying a store or a factory. You are buying 15 employees and one biology idea.
How they make money
n/a
annual revenue
The products that matter
Phase 3 liver disease program
Belapectin (GR-MD-02)
the only clinical asset that matters on this page
This is the whole economic story right now. The company is pre-revenue, so there is no approved product offset if belapectin stumbles. In plain English: one drug candidate is carrying the stock.
binary catalyst
Key numbers
-$0.76
fy2024 eps est
n/a
fy rev est
n/a
trailing p/e
n/a
dividend yield
Financial health
C+
strength
- balance sheet grade C+ — weak — may struggle to fund operations
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
C+ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for GALT right now.
source: institutional data · return history unavailable
What just happened
missed estimates
The last quarter showed a -$0.40 EPS, while revenue stayed undisclosed.
That is a loss, not a business with sales. Yahoo shows trailing EPS at -$0.52, so the red ink is not a one-quarter fluke.
$0M
revenue
-$0.40
eps
-$0.52
trailing eps
quarterly loss
The -$0.40 EPS loss matters most because it shows the company is still burning cash with no reported revenue.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
GALT is not facing generic biotech risk. It is facing one very specific problem: belapectin has to clear the clinical bar before the financing window gets tighter. With no revenue and one asset doing the heavy lifting, setbacks do not stay contained.
med
single-asset binary risk
One drug candidate carries the whole equity story. If belapectin disappoints in Phase 3, there is no approved product or broader commercial base on this page to absorb the damage.
impact: 100% of the current thesis sits on one clinical outcome.
med
cash burn meets a dated runway
Q3 2024 posted an $11.2M net loss, and the July 2025 credit line only points operations through June 2026. If timelines slip, the market starts pricing the next raise before it sees the next win.
impact: more dilution or more debt could arrive before any approval path becomes clearer.
med
no revenue cushion
There is no product revenue. A -87% return on assets tells you the assets are funding research, not producing income. When there is no cushion, every disappointment goes straight through to valuation.
impact: bad news does not hit earnings growth. It hits the existence of the business model.
med
volatility can outrun fundamentals
At roughly a $199M market cap with price stability at 5 / 100, this can move hard on financing headlines, conference commentary, or changing conviction among concentrated holders.
impact: even if your thesis is right later, the path to later can still be punishing.
The whole setup is a race between evidence and runway. If evidence slips, the financing story becomes the stock story.
source: institutional data · regulatory filings · risk analysis
Pay attention to
catalyst
the next real belapectin data point
This matters more than anything else on the page. One Phase 3 asset is carrying a $199M market cap and the full commercial hope.
funding
runway beyond June 2026
The $10M credit line solved the immediate problem, not the permanent one. Any update on extension, refinancing, or dilution matters because cash is part of the thesis.
burn
whether quarterly losses stay near $11.2M
With no revenue, spending discipline is one of the few operating signals you can track. If losses widen, the June 2026 date gets closer in market terms before the calendar says so.
holders
whether institutions stay patient
Institutional ownership sits at 67.8%. If that base starts reducing exposure before a clinical win, volatility can get worse fast in a $199M stock.
Analyst rankings
earnings predictability
75 / 100
in human-speak, analysts think the losses are relatively easy to model because there is no operating complexity here yet — just burn, runway, and trial timing.
risk rank
5
This sits near the bottom of the safety stack. You are being paid with optionality, not stability.
beta
1.1
Beta measures market sensitivity. A 1.1 beta says it moves a bit more than the market, then the biotech-specific headlines do the rest.
source: institutional data
Institutional activity
institutional ownership data for GALT is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$7
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive